Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CONMED Corporation filings document the regulatory record for a medical technology company with common stock listed on the NYSE under the symbol CNMD. Its Form 8-K reports cover quarterly and annual operating results, investor presentations furnished under Regulation FD, finance leadership changes, and portfolio actions involving gastroenterology products and distribution agreements.
The company’s proxy materials disclose board matters, annual meeting voting, executive compensation, equity awards, and related governance information. CONMED’s filing record also identifies its capital stock structure, including common stock with $0.01 par value, and provides formal exhibits for earnings releases, presentations, transition agreements, and other material corporate updates.
CONMED Corp executive Brent Lalomia reported equity awards that increase his stake-based compensation. On March 2, 2026, he acquired 9,554 RSUs, each representing one future share of common stock, and 11,322 stock options granted at no cost per option.
The RSUs generally vest over three years in 33%, 33%, and 34% annual installments, while the options generally vest in four equal annual installments. Both awards were granted under CONMED’s 2025 Long-Term Incentive Plan, tying a portion of his compensation to the company’s longer-term performance.
Foust Hollie K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that its General Counsel and Corporate Secretary, Hollie K. Foust, received equity awards in the form of restricted stock units and stock options. The grant included 10,919 RSUs, each representing a right to receive one share of CONMED common stock.
The RSUs were awarded under the company’s 2025 Long-Term Incentive Plan and generally vest over three years, with 33% vesting after the first and second years and 34% after the third year. Foust was also granted 12,940 options to purchase common stock under the same plan, which generally vest in equal 25% installments over four years starting one year after the grant date.
CONMED Corp reported that VP Corporate Controller Andrew James Moller acquired 5,896 restricted stock units (RSUs) as a grant of equity compensation. Each RSU represents a contingent right to receive one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and the remaining 34% after three years, subject to the terms of the company’s 2025 Long-Term Incentive Plan.
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received new equity awards, increasing her direct holdings through compensation grants rather than open‑market trades. On March 2, 2026, she was granted 28,800 RSUs, each representing a right to one CONMED common share, and 68,258 stock options.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% the second year, and 34% the third year under CONMED’s 2025 Long-Term Incentive Plan. The stock options were also granted under the 2025 plan and generally vest in equal 25% installments over four years, beginning one year after the grant date.
CONMED Corp director Mark Kaye reported acquiring 152 shares of common stock through the exercise and conversion of 152 RSUs on February 24, 2026. Each RSU represents a right to receive one share of common stock under the company’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan.
The RSUs generally vest 100% after one year, with vesting accelerated immediately if the director’s service terminates. After this transaction, Kaye directly holds 152 shares of CONMED common stock.
CONMED Corporation filed its annual 10-K detailing 2025 performance and risks. Consolidated net sales rose to $1,374,724,000, up from $1,307,015,000 in 2024 and $1,244,744,000 in 2023, with orthopedic surgery contributing 42% of sales and general surgery 58%.
The business is heavily driven by recurring single-use products, which represented about 78% of orthopedic surgery revenue and 92% of general surgery revenue in 2025. International markets accounted for roughly 32% of consolidated net sales, and no single customer generated more than 10% of revenue.
As of June 30, 2025, non-affiliate market value was approximately $1.2 billion, and 30,833,536 common shares were outstanding as of February 11, 2026. The company reports total debt of $840 million, including 2.250% Convertible Notes due 2027, and highlights risks related to leverage, regulation, supply chain, cybersecurity and evolving healthcare reimbursement.
CONMED Corporation filed a current report to let investors know it has released its financial results for the fourth quarter ended December 31, 2025. The company issued a press release on January 28, 2026, and attached it as Exhibit 99.1 to this report.
The filing clarifies that the earnings information in Item 2.02 and the press release are being furnished, not filed, which affects how they are treated under securities laws and how they may be incorporated into other regulatory documents.
CONMED Corporation is sharing an investor presentation as part of its appearance at the J.P. Morgan Healthcare Conference on January 12, 2026. The presentation, furnished as Exhibit 99.1, includes the company’s preliminary 2026 financial guidance and is available on its website in the Investors section under News & Events – Presentations.
The information in this report and the attached presentation is being furnished rather than filed under U.S. securities laws, which means it is not automatically subject to certain liability provisions or incorporated into other filings unless specifically referenced.
CONMED Corporation reported a planned transition of its Chief Financial Officer, Todd Garner. His separation as CFO will be effective on the earlier of March 15, 2026 or the appointment of a new permanent CFO, while he remains employed through November 2, 2026 to support a smooth transition. The company has engaged an executive search firm and begun a comprehensive search for the next CFO.
Garner will receive severance benefits under the company’s Executive Severance Plan in connection with a Qualifying Termination, and will continue to receive his current compensation, benefits, and eligibility for his 2025 annual bonus during the transition period, but will not receive a 2026 annual equity award grant. During the subsequent consulting period, he will receive his current base salary and may earn a pro‑rated 2026 cash bonus, subject to conditions including no termination for cause or breach of agreements. His existing equity awards will continue to vest through November 2, 2026, and the company states that his separation did not result from any disagreement over operations, policies, financial results, or accounting practices.
CONMED Corporation executive Brent Lalomia, Executive VP RA, QA, reported annual changes in indirect ownership of CONMED common stock for the fiscal year ended 12/31/2025. Between January 1, 2025 and December 31, 2025, he acquired 31.626 shares of CNMD common stock through the company’s 401(k) plan at a reported price of $40.6 per share. As of December 31, 2025, his 401(k) plan held a total of 125.232 shares of CONMED common stock, reported as indirectly owned. No derivative securities were reported.